Neurocrine Biosciences, Inc. (NBIX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 10:07AM EDT. Market open.
Show:
Annual
Cash flow
All numbers in thousandsBreakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Cash flows from operating activities
Net income
369,700
249,700
154,500
89,600
407,300
-
Depreciation & amortisation
22,500
21,300
15,600
10,900
8,600
-
Deferred income taxes
-40,700
-56,700
19,100
4,300
-310,700
-
Stock-based compensation
198,900
194,300
173,100
134,200
100,000
-
Change in working capital
54,100
28,200
-67,400
16,700
-37,900
-
Accounts receivable
-58,900
-89,300
-162,200
-28,400
-30,500
-
Inventory
4,700
5,400
-2,600
-2,500
-10,700
-
Other working capital
614,400
361,600
322,900
233,100
217,600
-
Other non-cash items
92,000
-200
1,600
14,300
25,100
-
Net cash provided by operating activities
645,400
389,900
339,400
256,500
228,500
-
Cash flows from investing activities
Investments in property, plant and equipment
-31,000
-28,300
-16,500
-23,400
-10,900
-
Acquisitions, net
-
0
-42,700
0
-
-
Purchases of investments
-1,493,800
-1,411,200
-628,900
-804,700
-735,500
-
Sales/maturities of investments
1,044,800
972,400
511,000
697,900
750,500
-
Other investing activities
-
-
-
-
-
-68,855
Net cash used for investing activities
-480,000
-467,100
-177,100
-130,200
4,100
-
Cash flows from financing activities
Debt repayment
-
0
-279,000
-100
-186,900
-
Common stock issued
-
-
-
-
-
27,313
Net cash used provided by (used for) financing activities
127,000
65,300
-234,300
27,400
-157,800
-
Net change in cash
292,700
-11,600
-73,300
153,700
74,800
-
Cash at beginning of period
111,600
270,700
344,000
190,300
115,500
-
Cash at end of period
404,000
259,100
270,700
344,000
190,300
-
Free cash flow
Operating cash flow
645,400
389,900
339,400
256,500
228,500
-
Capital expenditure
-31,000
-28,300
-16,500
-23,400
-10,900
-
Free cash flow
614,400
361,600
322,900
233,100
217,600
-
© 2024 Yahoo. All rights reserved.